Payment overview · 2025
General Payments
$1,676.55
49 reported records · 16 companies
Healthcare provider profile · identity verified
Shalini Katikaneni, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1326221649
Verified facts
What the public records show
CMS Open Payments records show Shalini Katikaneni, MD received $1,676.55 in general payments during 2025 across 49 reported records.
Lilly USA, LLC accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Nuedexta by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $266.55 | 15.9% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $253.54 | 15.1% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $238.08 | 14.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $230.87 | 13.8% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $183.03 | 10.9% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $120.63 | 7.2% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $92.10 | 5.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.89 | 3.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $52.60 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.87 | 2.3% | 2 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $28.49 | 1.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $26.12 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.28 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.95 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.44 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.11 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,591.56 | 48 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $274.65 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $230.87 | 5 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $183.03 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $153.09 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.69 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $119.21 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $92.10 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.89 | 3 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $52.60 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.50 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
132 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
182 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2775 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 2035 | 168 |
| Gabapentin | Gabapentin | 2004 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1829 | 155 |
| Furosemide | Furosemide | 1717 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1360 | 110 |
| Donepezil Hcl | Donepezil Hcl | 1328 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1096 | 95 |
| Lisinopril | Lisinopril | 1063 | 85 |
| Losartan Potassium | Losartan Potassium | 1056 | 97 |
| Trazodone Hcl | Trazodone Hcl | 1039 | 100 |
| Potassium Chloride | Potassium Chloride | 1036 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1008 | 76 |
| Carvedilol | Carvedilol | 998 | 85 |
| Sertraline Hcl | Sertraline Hcl | 899 | 75 |
| Memantine Hcl | Memantine Hcl | 849 | 67 |
| Eliquis | Apixaban | 842 | 91 |
| Metformin Hcl | Metformin Hcl | 791 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 687 | 57 |
| Mirtazapine | Mirtazapine | 667 | 81 |
| Levetiracetam | Levetiracetam | 655 | 50 |
| Divalproex Sodium | Divalproex Sodium | 636 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 623 | 66 |
| Omeprazole | Omeprazole | 605 | 85 |
| Baclofen | Baclofen | 599 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 589 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 546 | 57 |
| Montelukast Sodium | Montelukast Sodium | 514 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 500 | 26 |
| Buspirone Hcl | Buspirone Hcl | 377 | 31 |
| Finasteride | Finasteride | 360 | 26 |
| Klor-Con M20 | Potassium Chloride | 349 | 37 |
| Xarelto | Rivaroxaban | 332 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 321 | 28 |
| Allopurinol | Allopurinol | 315 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 313 | 25 |
| Januvia | Sitagliptin Phosphate | 307 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 296 | 19 |
| Tramadol Hcl | Tramadol Hcl | 279 | 73 |
| Fluoxetine Hcl | Fluoxetine Hcl | 277 | 17 |
| Alprazolam | Alprazolam | 269 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 253 | 62 |
| Sucralfate | Sucralfate | 244 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 243 | 30 |
| Famotidine | Famotidine | 240 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 239 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 234 | 22 |
| Midodrine Hcl | Midodrine Hcl | 215 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 209 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 208 | 14 |
| Spironolactone | Spironolactone | 203 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 201 | 73 |
| Lorazepam | Lorazepam | 185 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 182 | 21 |
| Jardiance | Empagliflozin | 182 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 15 |
| Nifedipine Er | Nifedipine | 180 | 15 |
| Simvastatin | Simvastatin | 178 | 21 |
| Clonidine Hcl | Clonidine Hcl | 177 | 24 |
| Meloxicam | Meloxicam | 171 | 21 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 167 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 159 | 81 |
| Doxazosin Mesylate | Doxazosin Mesylate | 156 | suppressed |
| Latanoprost | Latanoprost | 149 | 29 |
| Atenolol | Atenolol | 143 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 139 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 138 | 13 |
| Entresto | Sacubitril/Valsartan | 136 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 136 | suppressed |
| Ezetimibe | Ezetimibe | 135 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 134 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 54 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 76 |
| Myrbetriq | Mirabegron | 132 | 13 |
| Primidone | Primidone | 130 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 129 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 125 | 61 |
| Risperidone | Risperidone | 121 | 11 |
| Amantadine | Amantadine Hcl | 120 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 116 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 112 | 23 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 109 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 108 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 108 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 107 | 19 |
| Celecoxib | Celecoxib | 106 | suppressed |
| Ranolazine Er | Ranolazine | 101 | suppressed |
| Methocarbamol | Methocarbamol | 96 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 94 | suppressed |
| Glipizide | Glipizide | 93 | suppressed |
| Azithromycin | Azithromycin | 90 | 28 |
| Olanzapine | Olanzapine | 90 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 90 | 52 |
| Prednisone | Prednisone | 89 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 55 |
| Tobramycin Sulfate | Tobramycin Sulfate | 88 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 87 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 85 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 80 | 16 |
| Gemtesa | Vibegron | 76 | suppressed |
| Pregabalin | Pregabalin | 76 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 74 | suppressed |
| Bupropion Xl | Bupropion Hcl | 73 | suppressed |
| Clonazepam | Clonazepam | 73 | 18 |
| Valsartan | Valsartan | 72 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | suppressed |
| Mupirocin | Mupirocin | 71 | 34 |
| Aptiom | Eslicarbazepine Acetate | 70 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 70 | suppressed |
| Tradjenta | Linagliptin | 69 | suppressed |
| Budesonide | Budesonide | 68 | 19 |
| Digoxin | Digoxin | 68 | suppressed |
| Calcitriol | Calcitriol | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 13 |
| Nystatin | Nystatin | 67 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 27 |
| Methimazole | Methimazole | 65 | suppressed |
| Efavirenz | Efavirenz | 63 | suppressed |
| Valproic Acid | Valproic Acid | 61 | suppressed |
| Bumetanide | Bumetanide | 60 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 59 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 30 |
| Methenamine Hippurate | Methenamine Hippurate | 53 | suppressed |
| Torsemide | Torsemide | 53 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | 20 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 52 | suppressed |
| Brilinta | Ticagrelor | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Nystop | Nystatin | 51 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 19 |
| Lithium Carbonate | Lithium Carbonate | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 47 | 19 |
| Glimepiride | Glimepiride | 47 | 12 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 44 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 41 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 40 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 17 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 34 | 17 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 26 |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 23 |
| Lactulose | Lactulose | 33 | 18 |
| Levofloxacin | Levofloxacin | 33 | 23 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 13 |
| Santyl | Collagenase Clostridium Hist. | 32 | 23 |
| Acetazolamide | Acetazolamide | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 31 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Letrozole | Letrozole | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Eplerenone | Eplerenone | 29 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Alogliptin | Alogliptin Benzoate | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Admelog Solostar | Insulin Lispro | 26 | 13 |
| Diazepam | Diazepam | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 12 |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 25 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Cholestyramine Light | Cholestyramine | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 14 |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Cabergoline | Cabergoline | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 15 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Nateglinide | Nateglinide | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | 14 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Meropenem | Meropenem | 17 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 16 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 16 | suppressed |
| Rifampin | Rifampin | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Kerendia | Finerenone | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Alprazolam Odt | Alprazolam | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nifedipine | Nifedipine | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | 11 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Portia | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
| Risperidone Er | Risperidone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,676.55 · 49 records | Lilly USA, LLC | AUSTEDO XR, Briviact, CABENUVA, Dexcom G6 Transmitter, EVENITY, KISUNLA, Kerendia, MOUNJARO, PASCAL, PROCLAIM, REXULTI, TZIELD, VRAYLAR, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error